AstraZeneca's Evusheld Retains Neutralizing Activity Against

LONDON (dpa-AFX) - AstraZeneca's (AZN.L, AZN) Evusheld, a long-acting antibody combination for the prevention of COVID-19, retained neutralizing activity against the Omicron variant, the company

Related Keywords

Washington , United States , London , City Of , United Kingdom , , Emergency Use Authorization , Astrazeneca , Evusheld , Etains , Neutralizing , Activity , Against , Micron , Variant , Studies ,